
    
      The primary objective is to investigate whether all doses (0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg,
      and 1.0 mg/kg) of ketamine are superior to active placebo (midazolam 0.045 mg/kg) therapy in
      the acute treatment of patients with treatment resistant depression within 72 hours (Day 3),
      when added to ongoing and stable antidepressant therapy.
    
  